106 related articles for article (PubMed ID: 22792463)
1. Relative Copy Number Variations of CYP2C19 in South Indian Population.
Devendran A; Uppugunduri CR; Sundaram R; Shewade DG; Rajagopal K; Chandrasekaran A
Mol Biol Int; 2012; 2012():643856. PubMed ID: 22792463
[TBL] [Abstract][Full Text] [Related]
2. Genetic variations and haplotypes of the 5' regulatory region of CYP2C19 in South Indian population.
Satyanarayana CR; Devendran A; Sundaram R; Gopal SD; Rajagopal K; Chandrasekaran A
Drug Metab Pharmacokinet; 2009; 24(2):185-93. PubMed ID: 19430176
[TBL] [Abstract][Full Text] [Related]
3. Influence of the genetic polymorphisms in the 5' flanking and exonic regions of CYP2C19 on proguanil oxidation.
Satyanarayana CR; Devendran A; Jayaraman M; Mannu J; Mathur PP; Gopal SD; Rajagopal K; Chandrasekaran A
Drug Metab Pharmacokinet; 2009; 24(6):537-48. PubMed ID: 20045989
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
[TBL] [Abstract][Full Text] [Related]
6. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
7. Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction.
Kiss ÁF; Vaskó D; Déri MT; Tóth K; Monostory K
Pharmacol Rep; 2018 Jun; 70(3):525-532. PubMed ID: 29665549
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.
Uppugunduri CR; Daali Y; Desmeules J; Dayer P; Krajinovic M; Ansari M
Curr Drug Metab; 2012 Oct; 13(8):1196-204. PubMed ID: 22804232
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.
Helsby NA; Lo WY; Sharples K; Riley G; Murray M; Spells K; Dzhelai M; Simpson A; Findlay M
Br J Cancer; 2008 Oct; 99(8):1251-5. PubMed ID: 18854824
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of promoter region polymorphisms of human CYP2C19 gene.
Satyanarayana Chakradhara Rao U; Devendran A; Satyamoorthy K; Shewade DG; Krishnamoorthy R; Chandrasekaran A
Mol Biol Rep; 2011 Aug; 38(6):4171-9. PubMed ID: 21152987
[TBL] [Abstract][Full Text] [Related]
11. The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians.
Rosemary J; Adithan C; Padmaja N; Shashindran CH; Gerard N; Krishnamoorthy R
Eur J Clin Pharmacol; 2005 Mar; 61(1):19-23. PubMed ID: 15662508
[TBL] [Abstract][Full Text] [Related]
12. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
[TBL] [Abstract][Full Text] [Related]
13. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.
Moyer AM; Suman VJ; Weinshilboum RM; Avula R; Black JL; Safgren SL; Kuffel MJ; Ames MM; Ingle JN; Goetz MP
Pharmacogenomics; 2011 Nov; 12(11):1535-43. PubMed ID: 21961651
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China.
Jin T; Zhang M; Yang H; Geng T; Zhang N; Feng T; Ma Y; Yuan D; Kang L
Xenobiotica; 2016 Jul; 46(7):634-640. PubMed ID: 26526657
[TBL] [Abstract][Full Text] [Related]
15. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.
Uckun Z; Baskak B; Ozel-Kizil ET; Ozdemir H; Devrimci Ozguven H; Suzen HS
J Clin Pharm Ther; 2015 Dec; 40(6):672-9. PubMed ID: 26343256
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.
Burns KE; Goldthorpe MA; Porteus F; Browett P; Helsby NA
Cancer Chemother Pharmacol; 2014 Mar; 73(3):651-5. PubMed ID: 24519754
[TBL] [Abstract][Full Text] [Related]
17. Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.
Tayeb HT; Bakheet DH; Zaza K; Wakil SM; Dzimiri N
J Pharm Pharmacol; 2015 Jul; 67(7):972-9. PubMed ID: 25684066
[TBL] [Abstract][Full Text] [Related]
18. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.
Contin M; Sangiorgi S; Riva R; Parmeggiani A; Albani F; Baruzzi A
Ther Drug Monit; 2002 Dec; 24(6):737-41. PubMed ID: 12451290
[TBL] [Abstract][Full Text] [Related]
19. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population.
Payan M; Tajik N; Rouini MR; Ghahremani MH
Med J Islam Repub Iran; 2015; 29():269. PubMed ID: 26793660
[TBL] [Abstract][Full Text] [Related]
20. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.
Thieme D; Rolf B; Sachs H; Schmid D
Int J Legal Med; 2008 Mar; 122(2):149-55. PubMed ID: 17992535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
